Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial.
Adolescent
Adult
Antioxidants
/ pharmacology
Biomarkers
/ metabolism
Blood Glucose
/ metabolism
Child
Diabetes Mellitus, Type 1
/ blood
Dietary Supplements
Female
Glycated Hemoglobin
/ metabolism
Humans
Hyperglycemia
/ blood
Hypoglycemic Agents
/ pharmacology
Insulin
/ blood
Kidney
Liver
Male
Malondialdehyde
/ blood
Middle Aged
Oxidative Stress
/ drug effects
Plant Extracts
/ pharmacology
Plants, Edible
/ chemistry
Resveratrol
/ pharmacology
Young Adult
hemoglobin A1c
hyperglycemia
oxidative stress
resveratrol
type 1 diabetes
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
06 Jan 2020
06 Jan 2020
Historique:
received:
01
11
2019
revised:
23
11
2019
accepted:
04
12
2019
entrez:
16
1
2020
pubmed:
16
1
2020
medline:
18
11
2020
Statut:
epublish
Résumé
Resveratrol has been reported to be beneficial against diabetes complications. The objective of this study was to evaluate the efficacy of resveratrol in decreasing hyperglycemia in patients with type 1 diabetes (T1D) by a preliminary investigation designed as an exploratory clinical trial. Thirteen patients with T1D from both the sexes participated in this trial. All patients received resveratrol in 500 mg capsules, twice daily for 60 days. Bodyweight, fasting blood sugar (FBS), hemoglobin A1c (HbA1c), insulin, homeostasis model of assessment for insulin resistance (HOMA-IR), homeostasis model of assessment for β-cell function (HOMA-β), and markers of liver and kidney damage, inflammation, and oxidative stress were measured before the intervention, at 30 days and at 60 days. Resveratrol supplementation for 60 days significantly decreased FBS and HbA1c in comparison with the baseline values. Resveratrol treatment also resulted in a decrease in the level of a marker for oxidative stress, malondialdehyde, and an increase in total antioxidant capacity in T1D patients. Insulin, HOMA-IR, HOMA-β, and markers of liver and kidney function and inflammation were not significantly affected by resveratrol treatment. Overall, the results showed that 60 days of resveratrol supplementation exerted strong antidiabetic and antioxidant effects in patients with T1D.
Identifiants
pubmed: 31935938
pii: nu12010161
doi: 10.3390/nu12010161
pmc: PMC7019753
pii:
doi:
Substances chimiques
Antioxidants
0
Biomarkers
0
Blood Glucose
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin
0
Plant Extracts
0
Malondialdehyde
4Y8F71G49Q
Resveratrol
Q369O8926L
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Bushehr University of Medical Sciences
ID : IR.BPUMS.REC.1396.38.
Références
Diabetes Care. 2003 May;26(5):1589-96
pubmed: 12716823
Endocrinol Metab Clin North Am. 2010 Sep;39(3):481-97
pubmed: 20723815
Int J Exp Pathol. 2017 Dec;98(6):312-328
pubmed: 29285813
Int J Obes Relat Metab Disord. 1997 Mar;21 Suppl 1:S5-9
pubmed: 9130034
Ann N Y Acad Sci. 2013 Jul;1290:83-9
pubmed: 23855469
Eur J Endocrinol. 2011 Jul;165(1):77-84
pubmed: 21646283
Pharmacol Rep. 2012;64(6):1505-14
pubmed: 23406761
Diabetologia. 2013 Jul;56(7):1462-70
pubmed: 23613085
Diabetes. 2013 Oct;62(10):3500-13
pubmed: 23884882
Eur J Pharmacol. 2010 Jun 10;635(1-3):1-8
pubmed: 20303945
Int J Food Sci Nutr. 2015 May;66(3):314-20
pubmed: 25666415
Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1339-46
pubmed: 16434553
Curr Diab Rep. 2013 Dec;13(6):795-804
pubmed: 24072479
Obesity (Silver Spring). 2019 Jan;27(1):94-102
pubmed: 30569644
Diabetologia. 2010 Jun;53(6):1093-8
pubmed: 20237754
Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H696-703
pubmed: 21666113
Diabet Med. 2010 Apr;27(4):398-404
pubmed: 20536510
Diabetes Care. 2013 Jul;36(7):2009-14
pubmed: 23378621
Diabetes. 2011 Feb;60(2):634-43
pubmed: 21270273
Diabetes Care. 2015 Jun;38(6):971-8
pubmed: 25998289
Diabetes Care. 1998 Oct;21(10):1736-42
pubmed: 9773740
Biochimie. 2012 Feb;94(2):374-83
pubmed: 21864646
Phytother Res. 2019 Dec;33(12):3153-3162
pubmed: 31475415
Diabetes Care. 2013 May;36(5):1384-95
pubmed: 23589542
Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E853-63
pubmed: 21791624
Cardiol J. 2014;21(1):39-46
pubmed: 23677724
J Cell Physiol. 2019 Nov;234(11):20443-20452
pubmed: 31037738
Diabetes Care. 2018 Dec;41(12):2552-2559
pubmed: 30352894
Mol Nutr Food Res. 2015 Jan;59(1):147-59
pubmed: 25138371
Am J Clin Nutr. 2014 Jun;99(6):1510-9
pubmed: 24695890
Diabetes Care. 2010 Oct;33(10):2175-7
pubmed: 20696865
Nutr Res. 2012 Jul;32(7):537-41
pubmed: 22901562
Evid Based Complement Alternat Med. 2013;2013:851267
pubmed: 24073011
J Diabetes Res. 2016;2016:9737483
pubmed: 28050570
Biomed Pharmacother. 2008 Nov;62(9):598-605
pubmed: 18675532
JAMA. 1998 Jul 8;280(2):140-6
pubmed: 9669786
Endocr J. 2012;59(2):103-9
pubmed: 22068111
J Biochem Mol Toxicol. 2012 Oct;26(10):384-92
pubmed: 22791351
Biomark Insights. 2016 Jul 03;11:95-104
pubmed: 27398023
Biochim Biophys Acta. 2015 Jun;1852(6):1145-54
pubmed: 25445538
JAMA. 2017 Jan 24;317(4):379-387
pubmed: 28118454
Nutr Metab (Lond). 2017 Sep 22;14:60
pubmed: 29018489
PLoS One. 2018 Oct 1;13(10):e0204499
pubmed: 30273360
Nutrients. 2018 Oct 04;10(10):
pubmed: 30287729
Biochim Biophys Acta. 2011 Jul;1812(7):719-31
pubmed: 21439372
Circulation. 2013 Jan 15;127(2):180-7
pubmed: 23212717
Food Funct. 2019 Sep 1;10(9):6042-6051
pubmed: 31486447
Diabetes Ther. 2018 Feb;9(1):349-361
pubmed: 29139080